HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Alfacalcidol

HCID 5282181
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
41294-56-8
Standard SMILES
C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O
InChIKey
OFHCOWSQAMBJIW-AVJTYSNKSA-N
Molecular formula
C27H44O2
Average molar mass
400.6 g/mol
Monoisotopic mass
400.33413065

Overview

Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a diol, a seco-cholestane, a hydroxycalciol and a member of D3 vitamins. It is functionally related to a calciol.

Names & identifiers

Preferred name
Alfacalcidol
IUPAC
trans-(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
English name
Alfacalcidol
Molecular formula
C27H44O2
Molecular weight
400.64

Names & synonyms

alfacalcidol41294-56-81-HydroxycholecalciferolAlphacalcidol1alpha-Hydroxyvitamin D3AlfarolEinsAlpha1-Hydroxyvitamin D31alpha-HydroxycholecalciferolAlsiodolOxydevitBondiol
Show more names
HYDROXYVITAMIN D3Alfacalcidiol1α-Hydroxyvitamin D3EtαUn Alfa
alpha-CalcidolOne-AlphaEtalphaAlfacalcidolumAlpha D3AlpharolTevabone1alpha-Hydroxy-vitamin D3

Database identifiers

CAS
41294-56-8
PubChem CID
5282181
DTXSID
DTXSID0022569
ChEMBL
CHEMBL1601669
ChEBI
CHEBI:31186
UNII
URQ2517572
EC Number
255-297-1
Nikkaji
J9.282G

Properties

Computed structural propertiesFilling in

XLogP
6.8
Topological polar surface area
40.5 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
2
Rotatable bonds
6
Heavy atoms
29
Formal charge
0
Complexity
643

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Secosteroids [ST03] -> Vitamin D3 and derivatives [ST0302]
Solubility · 2 items

<1 mg/mL

1.63e-03 g/L

Melting Point136 °C
Physical DescriptionSolid

Physicochemical properties

Melting point
134 · 134-136°C
Boiling point
531.5 · 531.5±50.0 °C(Predicted)
Density
1.01 · 1.01±0.1 g/cm3(Predicted)
storage temp.
20 °C · −20°C
solubility
Practically insoluble in water, freely soluble in ethanol (96 per cent), soluble in fatty oils.
form
White crystalline solid

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P262, P264, P270, P271, P280, P284, P301+P316, P302+P352, P304+P340, P316, P320, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 48 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationAlfacalcidol: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 2 (100%)

Toxicology

Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Alfacalcidol

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Safety data

F
8-10
PPE
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
wgk
3
rtecs
VS2851000
ridadr
UN 2811 6.1/PG 1
hs_code
29361000
risk_code

Chemistry & industry

Pharmacology

ATC Code · 3 items

A11CC03

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingThe active metabolite of alfacalcidol, 1,25-dihydroxyvitamin D, is transported to tissues via globulin, a specific transport protein.
Pharmacodynamics · 1 item

Alfacalcidol works to increase serum levels of calcium by stimulating intestinal calcium absorption, reabsorption of calcium from bone, and possibly the renal reabsorption of calcium. It also modestly promotes intestinal phosphorus absorption. In patients with renal failure, alfacalcidol increased intestinal calcium and phosphorus absorption in a dose-related manner. This increase in calcium and phosphorus levels occurs within three days following drug administration: this effect was reversed within three days of drug discontinuation. In patients with chronic renal failure, serum calcium levels were elevated while parathyroid hormone and alkaline phosphatase levels returned to normal levels within five days following alfacalcidol administration. Since alfacalcidol suppresses parathyroid hormone, a reduction in parathyroid hormone levels is achieved more rapidly in patients on intermittent intravenous therapy, with significant reductions occurring within three months of therapy. In patients receiving daily oral therapy of alfacalcidol, the time it takes alfacalcidol to normalize plasma calcium levels may be up to several months, possibly reflecting calcium being utilized for bone mineralization. In patients with nutritional osteomalacia, alfacalcidol increased calcium absorption with six hours of oral administration and the effects peaked at 24 hours.

Mechanism of Action · 1 item

In conditions like chronic renal failure, renal bone disease, hypoparathyroidism, and vitamin D dependent rickets, the kidneys' capacity for 1α-hydroxylation is impaired, leading to reduced production of endogenous 1,25-dihydroxyvitamin D and aberrated mineral metabolism. As an active and potent analog of vitamin D, alfacalcidol works to restore the functions and activities of endogenous 1,25-dihydroxyvitamin D.

Biological Half-LifeThe half-life of alfacalcidol ranges from three to four hours.

Related reactions

5 records
New reaction record
HRID 348784 reaction equation
HRID 348784As product
HRID 553331 reaction equation
HRID 553331As product
HRID 1758905 reaction equation
HRID 1758905As reactant
HRID 2259556 reaction equation
HRID 2259556As reactant
HRID 2259557 reaction equation
HRID 2259557As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
pka
14.43 · 14.43±0.40(Predicted)
color
White to Almost white
biological source
synthetic
λmax
264 nm · 264nm(Diethyl ether)(lit.)
Merck
14 · 14,4819
Stability
Light Sensitive
InChIKey
OFHCOWSQAMBJIW-GITLSTMWSA-N
SMILES
[C@@H]1(O)CC(=C/C=C2\CCC[C@@]3(C)[C@@]\2([H])CC[C@@H]3[C@H](C)CCCC(C)C)C(=C)[C@H](O)C1
CAS DataBase Reference
41294 · 41294-56-8(CAS DataBase Reference)
FDA UNII
2517572 · URQ2517572
ATC code
11 CC03 · A11CC03
EPA Substance Registry System
Alphacalcidol (41294-56-8)
UNSPSC Code
41116107 · 41116107
NACRES
79 · NA.79
Protein binding
Extensive plasma protein binding
Excreted unchanged in urine
13 % · 13%
Biological half-life
3 · <3 / -
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
300 · H300
Precautionary statements
301 · P301+P310+P330
PPE
3 · Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Hazard Codes
T+,Xi
Risk Statements
26 · 26/27/28-36/37/38
Safety Statements
28 · 28-36/37-45-36-26
RIDADR
2811 · UN 2811 6.1/PG 1
WGK Germany
3 · 3
RTECS
2851000 · VS2851000
F
8 · 8-10
HazardClass
6.1 · 6.1(a)
PackingGroup
I
HS Code
29361000 · 29361000
Storage Class
6.1 A · 6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
Hazard Classifications
1 Oral · Acute Tox. 1 Oral
26/27/28-36/37/38
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T+,Xi
safety_code
28-36/37-45-36-26
hazard_class
6.1(a)
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials
packing_group
I
Hazard statements
H300
Hazard Classifications
Acute Tox. 1 Oral
Precautionary statements
P301+P310+P330
Metabolism/Metabolites · 1 item

Alfacalcidol is rapidly converted in the liver to 1,25-dihydroxyvitamin D, which is essentially the metabolite of vitamin D that regulates calcium and phosphate metabolism. Alfacalcidol is further metabolized to other polar inactive metabolites, excreted primarily through the bile.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and ExcretionAlfacalcidol is absorbed passively and almost completely in the small intestine.
Cellular LocationsCytoplasm
Applications · 4 items

DescriptionAlfacalcidol(41294-56-8) is a vitamin D analog. It is important for the regulation of the bone metabolism. Alfacaldidol is a regulator of calcium and phosphorus metabolism, which helps calcium and phosphorus to be absorbed more effectively in the intestines. Thus, alfacalcidol is used to treat renal (kidney) bone diseases, rickets, osteoporosis, and patients with high or low activity of the parathyroid gland. Also, it is used to maintain normal calcium levels within the body. Alfacalcidol has significant effects on the immune system, including regulatory T cells. Alfacalcidol is furthermore used as a poultry feed additive to prevent tibial dyschondroplasia and increases phytate bioavailability.

UsesFor the treatment of osteoporosis, vitamin D-dependent rickets and osteomalacia

UsesA synthetic analog of Calcitiol (the hormonal form of vitamin D3), which shows identical potency with respect to stimulation of intestinal calcium absorption and bone mineral mobilization. Vitamin D source

General DescriptionHas biological properties similar to 1α-Hydroxyvitamin D2 (Cat. No. 679100). Converted to active Calcitriol (1α,25-Dihydroxyvitamin D3; Cat. No. 679101) in vivo. Inhibits the formation of nephrocalcinosis in streptozotocin-induced diabetic rats fed on low zinc diets.

Upstream & downstream products

Upstream raw materials

Lithium Aluminum Hydride3-Chloroperoxybenzoic acidEthylenediamine tetrakis(propoxylate-block-ethoxylate) tetrol4-Phenyl-1,2,3,6-tetrahydropyridine hydrochloride
Additional notes · 1 item

DefinitionChEBI: A member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in reg lation of the calcium balance and the bone metabolism.